

# 1           **The Seroprevalence of SARS-CoV-2 Antibody in** 2           **the Asymptomatic Population**

3  
4           **Robert L. Stout, PhD and Steven J. Rigatti, MD**  
5           **Clinical Reference Laboratory, Inc.**  
6           **8433 Quivira Rd Lenexa, KS 66215**

7  
8           Word count 561

9           References 5

10          Tables 2

11         Abstract

12         The seroprevalence of COVID-19 in the self-reported well US population is currently  
13         unknown. In September we tested a convenience sample of 63,106 life insurance  
14         applicants for COVID-19 and found a prevalence of 6.6%. This population was  
15         specifically selected because they were not being evaluated clinically but solely  
16         being tested for mortality risk. Using 2019 US census estimates this equals more  
17         than 11.1 million (bootstrap 95% CI: 10.8 – 11.5 million) asymptotically infected patients,  
18         which is double the number of cases reported to CDC as of September 1st.

19         Introduction

20         With the imminent introduction of vaccines for COVID-19 it is important to identify  
21         patients that have previously been asymptotically infected; they represent two-  
22         thirds of the infected population. They would be expected to have the least benefit  
23         from vaccination while also be the group at higher risk of adverse side effects. The  
24         prevalence of this group in the initial vaccine trials is not adequate to determine the  
25         residual risk of vaccine induced enhanced respiratory disease<sup>1</sup>. FDA has previously  
26         recognized this risk in their Direction to Vaccine Developers<sup>2</sup>.

27  
28         In the setting of a pandemic, clinical decisions regarding testing and treatment are  
29         based on symptoms and the prevalence of the disease in the population. With  
30         SARS-CoV-2 the spectrum of symptom severity is wide. In the most severe cases

31 testing may not be needed to determine the need for hospitalization, while in less  
32 severe illness testing becomes more necessary to determine the proper care setting  
33 and the need for isolation. A testing strategy is necessarily informed by knowledge  
34 of the disease prevalence in the population. In the case of SARS-CoV-2 these  
35 estimates have largely been based on the number of laboratory-confirmed cases  
36 reported to the CDC as per their mandate<sup>3</sup>. However, because SARS-CoV-2 is  
37 known to produce asymptomatic infection, and not all who are symptomatic obtain  
38 testing, these reported cases necessarily underestimate the total burden of infection  
39 in the population. Since SARS-CoV-2 antibodies persist for weeks or months after  
40 infection, the prevalence of these antibodies in a population sample may produce a  
41 better estimate of the overall cumulative prevalence of infection.

42 **Methods:** A national convenience sample of 63,106 life insurance applicants was  
43 tested for the presence of antibody to SARS-CoV-2. Blood was obtained as part of  
44 the usual underwriting requirements for life insurance. This population was selected  
45 because they were not being evaluated clinically to diagnosis an illness and were  
46 individuals that self-reported they were healthy.

47

48 **Results:** The rate of seroprevalence varied widely by state, was slightly higher for  
49 females than males, and was strongly negatively associated with age. To estimate  
50 the total burden of SARS-CoV-2 infections in the US the total 2019 estimated  
51 census population was multiplied by the US population proportion between the ages  
52 of 16 and 80 (75.5%). Then, the state-specific proportion of positive tests was  
53 applied from our sample. Confidence limits were estimated by generating 5000  
54 bootstrap samples (with replacement) of our data and recalculating the total number  
55 of US cases. All statistical analyses were performed using R (version 3.6.1) and R-  
56 studio (version 1.2.1335)<sup>4</sup>.

57

58 Characteristics of the study population are displayed in Table 1. The distribution by  
59 state is displayed in Table 2. Our seroprevalence-based estimate suggests that  
60 approximately twice the number of SARS-CoV-2 infections have occurred than have  
61 been reported to the CDC. This suggests a much more widespread pandemic, but

62 with lower case rates of hospitalization, complications and deaths. Weaknesses of  
63 the study include an imbalanced representation of the US states, as well as the lack  
64 of samples from those under age 16 or over age 80. Even with these stated  
65 limitations the study validates the need for population wide surveillance; for the  
66 practicing physician the prevalence data provides a guide to relative risk of infection  
67 in their minimally or asymptomatic patient population.

68 While the debate continues about the degree and durability of protection afforded by  
69 prior infection the concern about adverse events may discourage many patients  
70 from vaccination. With the limited availability of vaccine it is important to preselect  
71 the population at highest risk that is likely to have the greatest benefit. Individuals  
72 that have had SARS-CoV-2 or that are antibody positive should defer vaccination  
73 until the vaccine is more widely available.

74 Additional information:

75 Statement of conflicting interest:

76 Neither Robert Stout, PhD nor Steven Rigatti, MD has any competing interest. Both  
77 authors have complete access to all the data in the study and take responsibility for  
78 the integrity of the data and analysis.

79

80 Western IRB reviewed the study under the Common Rule and applicable guidance  
81 and determined it is exempt under 45 CFR § 46.104(d)(4) using de-identified study  
82 samples for epidemiologic investigation.

83

84 This article has been submitted and approved as a preprint on  
85 medRxiv<sup>5</sup>. <https://medrxiv.org/cgi/content/short/2020.11.10.20215145v1>.

86

## 87 REFERENCES

- 88 1.) Tseng C-T, Sbrana E, Iwata-Yoshikawa N, Newman PC, Garron T, Atmar  
89 RL, et al. (2012) Immunization with SARS Coronavirus Vaccines Leads to  
90 Pulmonary Immunopathology on Challenge with the SARS Virus. PLoS ONE  
91 7(4): e35421. <https://doi.org/10.1371/journal.pone.0035421>
- 92 2.) FDA Nonbinding recommendations for “COVID-19-Related Guidance

93 Documents for Industry, FDA Staff, and Other Stakeholders,” available at  
94 [https://www.fda.gov/emergency-preparedness-and-response/mcm-](https://www.fda.gov/emergency-preparedness-and-response/mcm-issues/covid-19-relatedguidance-documents-industry-fda-staff-and-other-stakeholders)  
95 [issues/covid-19-relatedguidance-documents-industry-fda-staff-and-other-](https://www.fda.gov/emergency-preparedness-and-response/mcm-issues/covid-19-relatedguidance-documents-industry-fda-staff-and-other-stakeholders)  
96 [stakeholders](https://www.fda.gov/emergency-preparedness-and-response/mcm-issues/covid-19-relatedguidance-documents-industry-fda-staff-and-other-stakeholders)

97 3.) Nationally Notifiable Diseases Surveillance System. Coronavirus disease  
98 2019 (SARS-COV-2). Accessed July 29, 2020.

99 [https://wwwn.cdc.gov/nndss/conditions/coronavirus-disease-2019-SARS-](https://wwwn.cdc.gov/nndss/conditions/coronavirus-disease-2019-SARS-CoV-2/)  
100 [CoV-2/](https://wwwn.cdc.gov/nndss/conditions/coronavirus-disease-2019-SARS-CoV-2/)

101 4.) Studio Team (2020). RStudio: Integrated Development for R. RStudio, PBC,  
102 Boston, MA URL <http://www.rstudio.com/>.

103 5.) A preprint is posted on medRxiv: The Seroprevalence of SARS-CoV-2  
104 Antibody in the Asymptomatic Population

105105

**106** <https://medrxiv.org/cgi/content/short/2020.11.10.20215145v1>

107107

108 Statement of author contribution:

109 Robert Stout directed the testing of samples, combined the demographic data and  
110 then deleted all identifiable personal information. Reviewed all patient data for  
111 completeness and prepared the initial prevalence estimates.

112 Steve Rigatti Analyzed the prevalence for the data set statistically prepared the  
113 boot-strap adjusted individual state prevalence. He prepared the estimates for  
114 national and state prevalence of asymptomatic COVID-19 infection. Both authors  
115 prepared the text

Tables 1-2

Table 1: Characteristics of study population by SARS-CoV-2 antibody status.

Numeric values shown as median [IQR].

1 p-value by Pearson Chi-square test.

	Negative (58,926)	Positive (4180)	Total
Sex (% male)	55.3%	53.0%	0.002
Age (yrs)	42 [34-54]	41 [33, 52]	0.000
<30	7746 (90.2%)	837 (9.8%)	8583
30 - 39	17096 (93.3%)	1230 (6.7%)	18326
40 - 49	13537 (93.3%)	976 (6.7%)	14513
50 - 59	10942 (94.1%)	688 (5.9%)	11630
60 - 69	7046 (95.6%)	321 (4.4%)	7367
70+	2559 (95.2%)	128 (4.8%)	2687
Total	58926 (93.4%)	4180 (6.6%)	63106

Table 2: Seroprevalence for September by state.

	%		%		%
NY	15.39	AZ	4.34	CO	2.82
NJ	9.37	SC	4.27	OK	2.83
LA	7.95	MO	4.18	WA	2.53
MS	6.31	MA	4.14	KY	2.41
NV	6.18	RI	3.99	NH	2.34
DC	6.07	PR	3.9	UT	2.14
CT	5.99	TN	3.87	NC	2.13
FL	5.85	IN	3.69	VT	2.05
DE	5.59	IA	3.35	ND	1.81
GA	5.48	AR	3.29	WV	1.74
MD	5.34	NE	3.24	MT	1.57
MI	5.02	PA	3.23	HI	1.33
KS	4.94	ID	3.15	NM	1.33
IL	4.88	MN	3.15	WY	1.33
TX	4.85	WI	3.13	OR	1.18
AL	4.83	VA	3.07	ME	0.42
SD	4.44	OH	3.05	AK	0
		CA	3.04		